Price
CHART BY
Frequently asked questions
What is Blueprint's market capitalization?
The market capitalization of Blueprint is $5.73B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Blueprint?
Blueprint's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.108. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Blueprint's stock?
Currently, 21 analysts cover Blueprint's stock, with a consensus target price of $125.58. Analyst ratings provide insights into the stock's expected performance.
What is Blueprint's revenue over the trailing twelve months?
Over the trailing twelve months, Blueprint reported a revenue of $434.41M.
What is the EBITDA for Blueprint?
Blueprint's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$262.13M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Blueprint?
Blueprint has a free cash flow of -$250.52M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Blueprint have, and what sector and industry does it belong to?
Blueprint employs approximately 655 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Blueprint's shares?
The free float of Blueprint is 61.55M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $5.73B
- EPS (TTM)
- -$2.108
- Free Float
- 61.55M
- Revenue (TTM)
- $434.41M
- EBITDA (TTM)
- -$262.13M
- Free Cashflow (TTM)
- -$250.52M
Pricing
- 1D span
- $90.20$90.60
- 52W span
- $72.25$121.80
Analyst Ratings
The price target is $125.58 and the stock is covered by 21 analysts.
Buy
15
Hold
5
Sell
1
Information
Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
- Employees
- 655
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- US09627Y1091
- Primary Ticker
- BPMC